Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wai Bong

Physician Assistant, Medical Flushing, NY Physician Assistant

NPI 1184020315 CMS profile 10743778

13811 63Rd Ave, Flushing, NY 11367

Open in the dashboard

General payments

$61,933

844 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wai Bong of Flushing, NY is reported in the CMS Open Payments database as having received $61,933 across 844 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,073 150
2024 General $16,736 197
2023 General $10,007 181
2022 General $12,823 143
2021 General $12,295 173

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wai Bong
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Wai Bong were reported at $10,073. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Wai Bong Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $12,295 $156 $41–$563 $132
2022 $12,823 $185 $55–$649 $149
2023 $10,007 $199 $58–$717 $160
2024 $16,736 $206 $62–$740 $164
2025 $10,073 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $33,756 203 payments
  2. IBSA Pharma Inc. $5,925 43 payments
  3. Amgen Inc. $4,941 77 payments
  4. AstraZeneca Pharmaceuticals LP $2,619 46 payments
  5. Gilead Sciences, Inc. $1,630 40 payments
  6. Novo Nordisk Inc $1,570 44 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $1,111 19 payments
  8. Esperion Therapeutics, Inc. $999 22 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $816 45 payments
  10. Ardelyx, Inc. $804 33 payments
  11. Other $7,764 272 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $31,131 788 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,950 30 payments
  3. Consulting Fee $4,525 10 payments
  4. Education $218 12 payments
  5. Travel and Lodging $109 4 payments
Products named General payments · program years 2021–2025
  1. CREON $18,627 98 payments
  2. Licart $5,925 43 payments
  3. Flector $2,359 21 payments
  4. UBRELVY $1,752 45 payments
  5. EVENITY $1,490 29 payments
  6. Repatha $1,416 24 payments
  7. QULIPTA $1,347 31 payments
  8. Otezla $1,185 24 payments
  9. NEXLETOL $999 22 payments
  10. BREZTRI $896 8 payments
  11. Other $20,809 733 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 166 drugs

Part D claims

9,556

Median for Physician Assistant: 241

Drug cost

$1,475,532

Median for Physician Assistant: $4,110

Branded share of claims

25.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vascepa Icosapent Ethyl Brand 352 $179,016
Creon Lipase/Protease/Amylase Brand 60 $177,829
Diclofenac Epolamine Generic 175 $129,209
Budesonide Er Budesonide Brand 41 $89,582
Linzess Linaclotide Brand 143 $81,833
Diclofenac Sodium Generic 192 $69,919
Vemlidy Tenofovir Alafenamide Brand 31 $44,574
Eliquis Apixaban Brand 46 $42,092
Farxiga Dapagliflozin Propanediol Brand 65 $40,818
Rybelsus Semaglutide Brand 34 $37,462

The 10 drugs with the highest cost, of 166 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 50 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CREON
$6,223 60 —
Licart
$1,465 30 —
EVENITY
$516 15 —
FARXIGA
$483 65 —
Repatha
$436 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 50 with Patron

Records

844 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record